Shyam Joshi is a Rheumatology/Immunology physician affiliated with Oregon Health & Science University. OpenAlex indexes 86 publications with 761 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3181 SW Sam Jackson Park Rd
Portland, OR 97239
Telephone
503-494-4300Registry record last updated 16 Aug 2018.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202518 payments$25,804openpaymentsdata.cms.gov ↗
- GlaxoSmithKline, LLC.Program year202514 payments
- GENZYME CORPORATIONProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
54.8%Leukotriene Receptor Antagonist17.5%Montelukast Sodium100%Part D≥13 patientsCorticosteroid13.9%Budesonide-Formoterol Fumarate39%Breo Ellipta35%Breyna26%Part D<11 patients+ 5 more classes in this area
Dermatology
28.3%Interleukin-4 Receptor alpha Antagonist28.3%Dupixent Pen63%Dupixent Syringe37%Part D<11 patientsBlood & clotting
7.5%Antifibrinolytic Agent3.9%Tranexamic Acid100%Part D<11 patientsPlasma Kallikrein Inhibitor3.6%Takhzyro100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Breaking the Allergy Label: Safety of Inpatient Cefepime Challenges
Journal of Allergy and Clinical Immunology
2026 - Shared Decision-Making in Food Protein–Induced Enterocolitis Syndrome
The Journal of Allergy and Clinical Immunology In Practice
2025 - IVIG REFRACTORY HYPOGAMMAGLOBULINEMIA IN SECONDARY IMMUNODEFICIENCY
Annals of Allergy Asthma & Immunology
2025 - CHANGES IN PULMONARY FUNCTION FOLLOWING ENDOSCOPIC SINUS SURGERY
Annals of Allergy Asthma & Immunology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Orwoll, MD
Oregon Health & Science University
Aaron Caughey, MD
Oregon Health & Science University
Tomasz Beer, MD
Oregon Health & Science University
John Nutt, MD
Oregon Health & Science University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”